Symeres’ Post

In a new study we introduce an AI-assisted drug discovery approach and use it to generate over 14.9 million novel peptides with appealing pharmaceutical features, including molecules that inhibit key proteins linked to coronavirus infection and cancer in the lab. This research was led by Patrick Salveson, Ph.D., a recent postdoc in the Baker Lab. It led to a spinout company, Vilya, which emerged from the Institute for Protein Design in 2022. The molecules developed in the study, which are ring-shaped peptides called macrocycles, have the potential to treat a wide range of health disorders. The number and diversity of macrocycles described in this study far exceed what has been found in nature, and roughly half satisfy the so-called ‘rule-of-five’ criteria for drug-like compounds. Read a summary and access the full paper on the Baker Lab blog: https://lnkd.in/gX5xNkpq

Could this be done with peptodmimetics?

The application of new and existing structural biology techniques are revolutionising the way drugs are designed; with the low-hanging fruit already taken, structure-based techniques are empowering biopharma to fiercely go after undruggable targets by understanding dynamic proteins with greater resolution and speed. Therefore, I am excited to release the brand-new agenda for the inaugural Structure-Based Drug Design Summit, the conference dedicated to Harnessing Integrative Structural Biology Techniques Including NMR, X-Ray Crystallography, Cryo-EM, Cryo-ET to Determine 3D Structures of Pharmacologically Relevant Targets and Propel Drug Design Be the first to view the full event guide here: https://lnkd.in/emHsbcpP  Key Topics include: ⚡ Dealing with hard-to-drug, dynamic proteins using the structural biology toolbox and integrating techniques across small molecules, peptides, vaccines, and biologics, with Novartis, Pfizer, AstraZeneca, GSK, UCB ⚡ Shining a spotlight on the theoretical and practicalities of structural techniques to maximise the opportunity in drug design, appreciating the strengths, limitations and complementary roles of the techniques with Servier, MD Anderson Cancer Center, Gilead Sciences, Bayer ⚡ Diving into protein samples and strategies to mitigate obstacles and harness the potential of each protein to achieve higher resolution structures with Merck Group and Johnson & Johnson Innovative Medicine ⚡ Evaluating computational and predictive AI tools in structure prediction to assess the usability and efficacy of predicted structures in drug design with AbbVie ⚡ Illuminating the emerging technologies, including Cryo-ET and time-resolved cryo-EM, in structure-based drug design to assess the potential in industry-based drug development with The Francis Crick Institute, Technische Universität Darmstadt, & Scripps Research Institute View the full event guide here: https://lnkd.in/emHsbcpP This is a conversation your structural team won’t want to miss to maximise the opportunity at your fingertips to drive the exploration of 3D protein structures for drug discovery and development, go after the once deemed hard-to-drug targets, and shake up the therapeutic landscape I hope to see you in Boston with your structural biology, drug discovery, and drug design peers and key opinion leaders and take away critical insights at the Structure-Based Drug Design Summit for the very first time! Trevor M. Mehmet Gul Garth Jones #structurebaseddrugdesignsummit #structurebaseddrugdesign #SBDD #drugdesign #drugdevelopment #therapeuticdevelopment #cryoem #xraycrystallography #crystallography #nmr #structuralbiology #structural #biology #smallmolecules #peptides #biologics #vaccines

In December, the UTHSC College of Pharmacy awarded its annual Seed Research Grants to UTHSC CoP faculty to further their research goals. These grants are designed to help faculty members generate preliminary data for new areas of research initiated by the investigators. This increase in preliminary data helps make CoP faculty more competitive when pursuing external funding opportunities, especially federal research funding. Congrats to the awardees! Daniel Collier, PhD, Assistant Professor, Department of Pharmaceutical Science (in collaboration with Drs. Bhupesh Singla and Dennis Leo) The Role of Endothelial P2XR7 Channels in Atherosclerosis and Vascular Dysfunction Jarrod R. Fortwendel, PhD, Professor, Department of Clinical Pharmacy and Translational Science Deep-sequencing-assisted, Spontaneous Suppressor Screening for the Identification of CotA-Mediated Mechanisms of Hyphal Morphogenesis Brian M. Peters, PhD, Associate Professor, Department of Clinical Pharmacy and Translational Science (in collaboration with Dr. Vanessa Leone, UW-Madison) Therapeutic Strategies Aimed at Neutralizing Candidalysin Activity Bhupesh Singla, PhD, Assistant Professor, Department of Pharmaceutical Sciences Role of Macrophage LGR4-Mediated Signaling in Atherosclerosis Chao-Yie Yang, Associate Professor, Department of Pharmaceutical Sciences (in collaboration with Dr. Dennis Leo) Targeting ST2/IL-33 Axis in Mast Cell Activation by Novel ST2 Inhibitors #uthscpharmacy #UTHSC #TopinTN

Join us for the discussion: Future Trends in Pharmaceutical Sciences 2024 CSPS/CC-CRS Symposium June 11, 2024 As the pharmaceutical industry evolves, young scientists face an exciting future filled with emerging trends and opportunities. Over the next 5-20 years, key developments include advancements in personalized medicine, the rise of biologics and gene therapies, and the integration of digital technologies like AI and data analytics. To prepare for this dynamic landscape, trainees should focus on developing versatile skill sets, staying up-to-date with industry changes, and building connections within both academia and industry. By understanding the future direction of pharma, trainees can position themselves for success and make informed decisions about their career journeys. Not just for trainees - all registrants should join us on June 11, 2024, for an insightful panel discussion featuring distinguished experts from academia and industry, who will share their perspectives on the future of pharmaceutical sciences. Haven't yet registered for the Symposium? It is not too late! Details of the Symposium, including the program, speakers and social activities being offered - including a social event dedicated to young scientists - are available on the symposium website: https://lnkd.in/eQMFkbjH Panelists: Afsaneh Lavasanifar; Amyn Sayani; John Ussher; Truong Ta Don't miss out - register today and join us in Edmonton for this enriching and engaging event: https://lnkd.in/ebMCUqZW #FuturePharma #YoungScientists #IndustryTrends

I will be participating in the roundtable and will try to provide comprehensive information on the following questions: How do I know if my idea is innovative? How and in what format should an idea be assessed to determine whether it is innovative and has prospects for commercialization? What influences the quality of a scientific idea and the direction a researcher chooses? How to harmonize research with the state-of-the-art in the world? Educating highly qualified personnel within the country: what is needed for this? How should the university-employer relationship be established? How can we solve the issue of ensuring the level of practical training?

𝐏𝐡𝐨𝐬𝐩𝐡𝐨 𝐅𝐀𝐊 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://lnkd.in/daMwRk36 🔬 The Phospho FAK Antibody Market is set to experience remarkable growth, driven by increasing research activities in cancer biology, cell signaling, and tissue engineering. Valued at approximately $300 million in 2023, the market is projected to reach around $600 million by 2032, reflecting a significant CAGR of 9.1%. This growth is fueled by the rising prevalence of cancer and the demand for advanced diagnostic and therapeutic solutions. Our comprehensive report provides both quantitative and qualitative insights into the Phospho FAK Antibody Market, examining manufacturers, regional analyses, types, and applications. It also features company profiles, product examples, and market share estimates for leading competitors in 2024. *𝗕𝘆 𝗧𝘆𝗽𝗲: Monoclonal Antibodies, Polyclonal Antibodies *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Research Institutions, Pharmaceutical Companies, Biotechnology Companies *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Cell Signaling Technology (CST), Abcam, Thermo Fisher Scientific, R&D Systems, Bio-Rad Laboratories, MilliporeSigma, Santa Cruz Biotechnology (SCBT), GenScript, OriGene, Fitzgerald Industries Intl- Biosynth, Hycult Biotech, Cayman Chemical, Aviva Systems Biology, Rockland Immunochemicals, Inc., Novus Biologicals, a Bio-Techne brand, Twist Bioscience, PeproTech, SouthernBiotech, Zymeda Provider Solutions, MyBioSource, Thermo Fisher Scientific, Acris Antibodies, BioLegend, MedChemExpress LLC, PeproTech, SeraCare, Alomone Labs #phosphofakantibodies #medicaldevices #biotechnology #cancerresearch #marketresearch #pharmaceuticals #antibodies #laboratory #CAGR #biomedical #research #immunology #clinicalresearch #diagnostics #cellbiology #drugdevelopment #biologics #researchinstitutions #pharmaceuticals #globalmarket #biochemistry

I am excited to share that I am guest editing an special issue on the British Journal of Biomedical Sciences! This Special Issue seeks to address current methods in nanomaterials design and fabrication for targeted drug delivery, approaches for cell-specific or organelle-specific delivery of drugs, and evidence of translational application in vitro and in vivo. We welcome original research papers and reviews that provide new insights into the design and application of nanomaterials in drug delivery systems that point to downstream clinical applications. Potential topics include, but are not limited to: • Novel biomaterials for targeted nanoparticle drug delivery • Innovative fabrication methods for drug delivery nanomaterials • Cell-specific or organelle-specific drug delivery strategies • Targeting ligands and receptor interactions • Intracellular trafficking and release • Biocompatibility and toxicity assessment • Translational challenges and clinical applications of nanomaterial-based drug delivery systems in health and disease. Submissions open! https://lnkd.in/eEN9Q7hk

In a significant stride for medical research, Hao Yan, a professor in Arizona State University’s School of Molecular Sciences and the Biodesign Center for Molecular Design and Biomimetics, has been awarded a $1.25 million grant from the National Institutes of Health (NIH). The grant, provided by the National Institute of General Medical Sciences (NIGMS), will fund Yan’s innovative research into programmable, targeted therapeutics. Targeted protein degradation (TPD) is a new approach in drug development that focuses on breaking down disease-causing proteins inside cells. Traditional drugs usually work by blocking the activity of specific proteins. However, about 85% of proteins in cells are considered "undruggable" with these traditional methods because they can't be effectively targeted by small-molecule drugs. TPD therapies take a different approach by using the cell's natural system for breaking down proteins to completely remove these problematic proteins. This method is especially useful for targeting proteins that are hard to inhibit directly. One type of TPD therapy, called proteolysis-targeting chimeras (PROTACs), uses the cell's ubiquitin-proteasome system — which is like the cell's trash disposal unit — to selectively degrade these tough-to-target proteins. While PROTACs have shown promise and some are already being tested in clinical trials, there are still significant challenges and opportunities for further development in this field. Yan’s project addresses unmet needs in targeted protein degradation therapeutics and develops a series of programmable and conditional PROTACs enabled by nucleic acid nanotechnology. “We are excited to receive this award from NIGMS to support our programmable and conditional PROTAC platforms,” Yan said, “and we believe we could utilize the high programmability of #DNA nanotechnology to address some of the unmet yet important challenges in this field.” #ASU #ASUBiodesign #ASUResearch

Join Carterra and WuXi Biologics at their upcoming symposium in Oxford, United Kingdom, on June 12th 2024.   You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include: ✅ Workflows enhancing the speed or efficiency of drug discovery ✅ AI and ML initiatives and in silico antibody discovery programs ✅ Small molecule applications: TPDs, DELs, PROTAC®s, Membrane Proteins ✅ Novel assay designs including HT-SPR applications ✅ Emerging modalities such as next-gen antibodies: scFVs, nanobodies, bi-specifics, ADCs ✅ Strategies to maximize impact in specific therapeutic areas such as immuno-oncology, infectious diseases, and neuroscience Come along to network with your peers. Lunch will be provided. Registration is required as seating is limited: https://lnkd.in/d9W95BWS #molecule #scienceevent #HTS #drugdiscovery